Minerva Neurosciences, Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for NERV, updated each market day.
NERV AI Sentiment
AI sees no strong directional signal for Minerva Neurosciences, Inc stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Minerva Neurosciences, Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Sector
Exchange
Market Cap
$260,511,875
Cap Tier
Employees
7
Headquarters
BURLINGTON, MA
Listed Since
July 1, 2014
NERV Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
NERV Volatility
Minerva Neurosciences, Inc has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
